Newsfiscal.ai
Lucid Diagnostics Begins Receiving Medicare Reimbursement and Closes $15 Million Financing
· Published
Article summary
Lucid Diagnostics has commenced receiving Medicare payments for its EsoGuard Esophageal DNA Test and successfully closed a $15 million private placement of Series C Convertible Preferred Stock.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…